Amylin Pharmaceuticals, Inc.

  • What GlaxoSmithKline's Latest Move Means for You

    By Jordo Bivona - July 25, 2012 | Tickers: AMLN, AZN, BMY, GSK, HGSI

    GlaxoSmithKline (NYSE: GSK) recently announced the completion of its acquisition of Human Genome Sciences (NASDAQ: HGSI) for approximately $3 billion. The acquisition will be completed at $14.25 a share, including cash and debt, valuing the target at $3.6 billion, a nearly 100% premium over Human Genome Science's stock price on April 18 when GlaxoSmithKline's intention was first announced. Aside from the obvious implications for the two more »

  • A Winner in the Booming Drug Market

    By Jordo Bivona - July 18, 2012 | Tickers: AMLN, AZN, BMY, LLY, JNJ

    The drug market is finally experiencing a boom in that drug manufacturers are focusing less on the broader market and more on finding cures and treatments for rare and deadly illnesses. Of course, regulatory bodies stand in their way, which means that the situation brings with it both winners and losers in the pharmaceutical industry. The winners and losers we will look at today are AstraZeneca (NYSE: AZN)Bristol-Myers Squibb more »

  • Amylin Deal Signals Diabetes Space is Hot

    By Tony Daltorio - July 6, 2012 | Tickers: AMLN, AZN, BMY, GSK, HGSI

    The bidding war for Amylin Pharmaceuticals (NASDAQ: AMLN) is over with a successful joint bid for the company by Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca PLC ADR (NYSE: AZN). In a two-part transaction, Bristol-Myers will first pay $5.3 billion cash to Amylin stockholders. It will also assume debt and royalties payable to Amylin's partner Eli Lilly for another $1.7 billion. 

    But then Bristol-Myers will fold the company more »

  • Strengthening the Portfolio

    By Muhammad Bazil - July 6, 2012 | Tickers: AMLN, AZN, BMY, LLY

    Amylin Acquisition

    Last Friday, the pharmaceutical maker Bristol-Myers Squibb (NYSE: BMY), acquired the diabetes drug maker Amylin (NASDAQ: AMLN) for $5.3 billion, or $31 per share. The total cost of the deal reflects a payment to Eli Lilly & Company (NYSE: LLY), and debt payment obligations that total $1.7 billion. The move now gives the company access to approval to supply and provide a set of diabetes medications. This more »

  • Which Big Pharma Will Own the Next Weight Loss Blockbuster?

    By REZA GANJAVI - July 2, 2012 | Tickers: AMLN, ARNA, BMY, JNJ, PFE

    Speculations are abundant around who and when Arena Pharmaceuticals (NASDAQ: ARNA) will be bought out. Most investors I've talked to believe a buyout is inevitable because:

    a) Arena has a blockbuster-potential drug just approved by the FDA.

    b) Big Pharma is in dire need of a lucrative acquisition to boost its pipeline. According to PricewaterhouseCoopers, by 2015 the top 10 Big Pharma companies stand to lose up to 40 more »

  • Billionaire Carl Icahn’s Favorite Stocks

    By Meena Krishnamsetty - June 14, 2012 | Tickers: AMLN, AZN, BMY, CHK, MRK

    At 76 years old, Carl Icahn does not seem to be slowing down at all. Last year Icahn did return his hedge fund's outside money to focus on investing his own funds but his activity as an activist shareholder does not seem to have waned significantly.

    Just recently he was proposing a new slate of directors for Forest Laboratories, which has been up ~18% YTD. Shareholder activists take an more »

  • Elm Ridge Capital’s Top Stock Picks

    By Meena Krishnamsetty - June 6, 2012 | Tickers: AMLN, AGO, LMT, MBI, MRK

    Ron Gutfleish runs hedge fund Elm Ridge Capital, with over $2 billion in AUM. Elm Ridge Capital returned an average of 9.5% between 2009 and 2011. Ron Gutfleish previously worked at Leon Cooperman’s Omega Advisors and Goldman Sachs. He has a Ph.D. from the University of California Berkeley. Below are his top 10 stock picks at the end of the first quarter (the activity column shows the more »

  • VIVUS, Weight Loss, and the Patient Investor

    By Jordo Bivona - June 4, 2012 | Tickers: ABT, AMLN, GSK, SNY, VVUS

    Right from the outset, a child is exposed to a number of body image ideals that establishes the fact that our society places a lot of importance on the way we look. Though naysayers dismiss the importance of one's looks and physical appearance, we all know it way to well that our physical appearance is responsible to some extent for the way we are treated by people around us more »

  • A Diamond in the Rough Among European Pharma

    By Meena Krishnamsetty - May 10, 2012 | Tickers: AMLN, BIIB, GSK, NVO, SNY

    European pharma has not had a great run recently, but we think we’ve found a diamond in the rough. Novo Nordisk (NYSE: NVO) is a Danish pharmaceuticals company that specializes in treatments for diabetes and haemostasis, the latter of which refers to the human body's response to blood vessel injury and bleeding. We see long term trends and expanding markets for the indications that NVO focuses on. In more »

  • AstraZeneca Needs the Right Formula

    By Tony Daltorio - April 11, 2012 | Tickers: AMGN, AMLN, AZN | Editor's Choice

    For the past several years, Anglo-Swedish pharmaceutical company AstraZeneca PLC ADR (NYSE: AZN) has struggled to adapt to the rapid changes occurring in the industry. Like the other major drug companies, AstraZeneca – the maker of the blockbuster cholesterol drug Crestor – is facing a number of expiring patents along with an ever thinner pipeline of new drugs to replace them.  

    Under its CEO David Brennan, it has lagged behind its peers more »

  • Amylin Ignites the Biotech Sector

    By Tony Daltorio - March 30, 2012 | Tickers: AMLN, AZN, BMY, LLY, SNY

    Word came out this week that Amylin Pharmaceuticals (NASDAQ: AMLN) turned down a $3.5 billion, $22 a share takeover offer from Bristol-Myers Sqiubb (NYSE: BMY). This rumored bid lit a fire under much of the biotechnology sector as the hopes of more acquisitions in the space was rekindled. According to Bloomberg, there have already been 16 acquisitions, valued at more than $1 billion each, in the sector over the more »

  • Amylin Rejected $3.5 billion Bid from Bristol-Myers Squibb

    By Meena Krishnamsetty - March 29, 2012 | Tickers: AMLN, AZN, BMY, LLY, NVO

    Bloomberg reported this morning that Bristol-Squibb Myers (NYSE: BMY) approached Amylin (NASDAQ: AMLN) with a $3.5 billion offer or $22 per share. The headlines indicate that the bid was rejected and that BMY has not resubmitted an offer. In prior press releases, it appeared that AMLN was looking for a commercial partner outside of the US. Finding a partner would imply the company is not selling itself. However, with more »

  • Amylin: Should You Consider This Biotech?

    By Bobby Fisher - March 6, 2012 | Tickers: AMLN, LLY, NVO

    Since 2008, diabetes stocks have dropped a full 27.6%, which leads to the question of whether investors should even bother considering this side of the market anymore.

    Let’s take a look at Amylin Pharmaceuticals Inc. (NASDAQ: AMLN), a mid-level company that is a large producer of diabetes medications, to see if it is worth buying into this biotech stock. The company’s 2011 fourth quarter results were down more »

  • Take the Long Road with Alkermes

    By Brandy Betz - February 5, 2012 | Tickers: ALKS, AMLN, BMY, ELN

    Biopharmaceutical company Alkermes (NASDAQ: ALKS) achieved a revenue increase of 185.7% in the third quarter of fiscal 2012, the first full quarter since the company acquired the drug delivery arm of Elan (NYSE: ELN). Zacks had predicted revenues of $113.0 million, 11% below the reported $125.6 million. The company also outperformed Zacks’ estimated 21 cents per share loss with a reported one cent per share loss. Though more »

  • FDA Approves Amylin Diabetes Drug

    By Brandy Betz - January 31, 2012 | Tickers: ALKS, AMLN, LLY

    The FDA granted approval Friday for Bydureon, a once weekly version of the Amylin (NASDAQ: AMLN) diabetes drug Byetta. The longer lasting dosage was made possible using dosage techniques created by Alkermes (NASDAQ: ALKS), which will receive 8% of the profits. Amylin closed Monday up over 17% to $14.26. Bydureon will have its official release next month.

    Byetta and Bydureon both contain the active ingredient exenatide, a synthetic version more »

  • Amylin Pharmaceuticals Motto: Try, Try, and then Try Again

    By Elizabeth Magill - January 28, 2012 | Tickers: ALKS, AMLN, LLY, NVO

    If first you don't succeed, try again. If you still don't succeed, try for number three.  It seems like the third time's a charm for drug maker, Amylin Pharmaceuticals (NASDAQ: AMLN).

    Roughly 26 million Americans and 285 million people worldwide suffer from diabetes. Some of these folks are going to be awfully glad that Amylin Pharmaceuticals didn't give up.

    Bydureon, one of the most anticipated new more »

  • J.P. Morgan Healthcare Conference Schedule: Day One

    By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ

    The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.

    I will be following (and covering) the novel therapeutic companies that have caught my eye. VIVUS (NASDAQ: VVUSmore »)